Quarterly report pursuant to Section 13 or 15(d)

Restatement of Previously Issued Financial Statements (Details)

v3.22.2.2
Restatement of Previously Issued Financial Statements (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Consolidated Statement of Operations        
Total Operating Revenue $ 273,544,334 $ 151,297,940    
Medical Expenses 265,820,802 146,624,505    
Total Operating Expenses 325,712,062 164,286,370    
Interest Expense, net (2,761,250) (2,124,286)    
Total Other Expenses (8,622,526) (11,662,282)    
Net Loss Attributable to Non-Controlling Interests (50,212,750)      
Net Loss (formerly Net Loss Attributable to Controlling Interests) $ (10,577,504) $ (24,650,712)    
Condensed Consolidated Statements of Changes in Members' Deficit        
Preferred return 8.00% 8.00%    
Net Loss $ 60,790,254 $ 24,650,712    
Balance end 262,973,992 (154,407,902) $ 273,551,441 $ (130,217,705)
Consolidated Statements of Cash Flows        
Net Loss 60,790,254 24,650,712    
Class A and Class D Preferred Returns 8      
Capitated Revenue        
Consolidated Statement of Operations        
Total Operating Revenue 269,684,815 148,964,190    
Other Patient Service Revenue        
Consolidated Statement of Operations        
Total Operating Revenue 3,859,519 2,333,750    
As Previously Reported        
Consolidated Statement of Operations        
Total Operating Revenue   151,564,380    
Medical Expenses   146,890,945    
Total Operating Expenses   164,552,810    
Interest Expense, net   (4,081,134)    
Total Other Expenses   (13,619,130)    
Net Loss Attributable to Non-Controlling Interests   (3,282,292)    
Net Loss (formerly Net Loss Attributable to Controlling Interests)   (23,325,268)    
Condensed Consolidated Statements of Changes in Members' Deficit        
Preferred Return at 8% for Class A Units   890,612    
Net Loss   (26,607,560)    
Balance end   (122,918,168)   (97,661,735)
Consolidated Statements of Cash Flows        
Net Loss   (26,607,560)    
Class A and Class D Preferred Returns   1,956,848    
As Previously Reported | Capitated Revenue        
Consolidated Statement of Operations        
Total Operating Revenue   147,700,465    
As Previously Reported | Other Patient Service Revenue        
Consolidated Statement of Operations        
Total Operating Revenue   3,863,915    
Network Adjustments        
Consolidated Statement of Operations        
Net Loss Attributable to Non-Controlling Interests   3,282,292    
Net Loss (formerly Net Loss Attributable to Controlling Interests)   (3,282,292)    
Preferred Returns Adjustments        
Consolidated Statement of Operations        
Interest Expense, net   1,956,848    
Total Other Expenses   1,956,848    
Net Loss (formerly Net Loss Attributable to Controlling Interests)   1,956,848    
Condensed Consolidated Statements of Changes in Members' Deficit        
Preferred Return at 8% for Class A Units   (890,612)    
Net Loss   1,956,848    
Balance end   5,633,581   4,567,346
Consolidated Statements of Cash Flows        
Net Loss   1,956,848    
Class A and Class D Preferred Returns   (1,956,848)    
Revenue Adjustments        
Consolidated Statement of Operations        
Total Operating Revenue $ 6,532,954 (266,440)    
Medical Expenses   (266,440)    
Total Operating Expenses   (266,440)    
Condensed Consolidated Statements of Changes in Members' Deficit        
Balance end   6,532,954   6,532,954
Revenue Adjustments | Capitated Revenue        
Consolidated Statement of Operations        
Total Operating Revenue   1,263,725    
Revenue Adjustments | Other Patient Service Revenue        
Consolidated Statement of Operations        
Total Operating Revenue   (1,530,165)    
Class A Units Adjustments        
Condensed Consolidated Statements of Changes in Members' Deficit        
Balance end   (43,656,269)   (43,656,270)
As Restated        
Consolidated Statement of Operations        
Total Operating Revenue   151,297,940    
Medical Expenses   146,624,505    
Total Operating Expenses   164,286,370    
Interest Expense, net   (2,124,286)    
Total Other Expenses   (11,662,282)    
Net Loss (formerly Net Loss Attributable to Controlling Interests)   (24,650,712)    
Condensed Consolidated Statements of Changes in Members' Deficit        
Net Loss   (24,650,712)    
Balance end   (154,407,902)   $ (130,217,705)
Consolidated Statements of Cash Flows        
Net Loss   (24,650,712)    
As Restated | Capitated Revenue        
Consolidated Statement of Operations        
Total Operating Revenue   148,964,190    
As Restated | Other Patient Service Revenue        
Consolidated Statement of Operations        
Total Operating Revenue   $ 2,333,750